A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02927769
- Phase
- PHASE2
- Status
- Completed
Conditions
- Hodgkin Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 30 Years
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — BIOLOGICALSpecified Dose on Specified Days
- brentuximab vedotin — BIOLOGICALSpecified Dose on Specified Days
- bendamustine — BIOLOGICALSpecified Dose on Specified Days
Study Details
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Key Dates
- Start date
- Mar 28, 2017
- Status verified
- Jan 2025
- Primary completion
- May 28, 2024
- Completion
- May 28, 2024
Study Design
- Enrollment
- 72 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Nivolumab + brentuximab vedotin
- Experimental: brentuximab vedotin + bendamustine
Primary Outcome Measure
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 [ Time Frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks). ]
Locations (43)
Related coverage on Hipa.ai
- Nivolumab Combo Shows High Response in Relapsed/Refractory Classic Hodgkin…Nivolumab · Feb 10, 2025 · ClinicalTrials.gov
Find similar trials in Birmingham, AL
By research site
Related Studies
- Tissue Collection for Studies of Lymph CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantPHASE2 · Recruiting · University of Rochester · Rochester, New York
- Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesPHASE1 · Recruiting · Medical College of Wisconsin · Milwaukee, Wisconsin